Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of care chemotherapy plus endocrine therapy (ET). The study investigates whether the patient group with high-risk early breast cancer benefits from treatment with the medication abemaciclib in combination with ET compared to ET alone.
Full description
The WSG ADAPT trial program is one of the first new generation trials addressing the issue of individualization of (neo)-adjuvant decision-making in early breast cancer (EBC) in a subtype-specific manner. The first WSG ADAPT umbrella trial (NCT01779206) aimed to establish early predictive molecular surrogate markers for response after a short 3-week induction treatment.
The goals of the WSG ADAPT trial program - early response assessment and subtype-specific therapy tailoring to those patients who are most likely to benefit - have contributed to the positive national and international feedback regarding the ADAPT-concept as a whole.
The aim of this ADAPTlate phase-III-trial is to gain further knowledge of the group of patients at intermediate to high risk for disease recurrence, who have completed definite locoregional therapy (with or without neoadjuvant or adjuvant chemotherapy). With ADAPTlate it is planned to investigate if the intermediate to high-risk patient group identified during the screening phase derives additional benefit from treatment with abemaciclib in combination with ET compared to ET alone.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A. Prior to REGISTRATION
patient underwent bilateral oophorectomy, or
age ≥ 60, or
age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, or ovarian suppression) and/or FSH and estradiol in the postmenopausal range per local normal range.
4b. OR: Pre-/perimenopausal patients:
confirmed negative serum or urine pregnancy test (β-hCG) before starting study treatment, or
patient has had a hysterectomy. 5. Histologically confirmed diagnosis(by local laboratory ) of estrogen-receptor positive and/or progesterone-receptor positive (>1% ) primary early breast cancer or local relapse. In case the receptor status from local pathology is unclear a central pathology review is obligatory. Results must be known prior to randomization.
a negative in-situ hybridization test or an IHC status of 0, 1+, or 2+,
if IHC is 2+, a negative in-situ hybridization (FISH, CISH, or SISH) test is required (based on the analyzed tissue sample at initial diagnosis by a local laboratory).
with completed (i.e., 5 years according to SoC), planned or ongoing adjuvant endocrine therapy, without any signs of distant relapse or secondary malignancy AND
if primary diagnosis was 6 years or less before enrollment 8a. Intermediate to high clinical or genomic risk, defined as either one of the following criteria:
c or p or ypN 2-3 with/without (neo)adjuvant chemotherapy;
in patients with c/ypN0-1:
non-pCR in patients with G3 or c/ypN1
high biological risk defined as G3 with Ki-67 ≥40%
or high genomic risk (RS>25 (known or Oncotype Dx® in screening phase) or another test)
high CTS5 score or UICC stage IIb (clinical if neoadjuvant chemotherapy or pathological)
OR, if patients do not fulfill above criteria:
ET non-response definition:
Ki-67 post-treatment > 10% (central or local pathology value) OR 8b. Patients after isolated locoregional relapse with high-risk patterns (e.g., rpT2-3 or rpN1-3 or G3 or Ki-67 pre-treatment ≥20%), once surgery with free margins was completed Note: Inclusion is only possible for the first locoregional relapse removed by surgery (free margins) OR 8c. Patients with any high clinical risk at Investigator´s assessment but not fulfilling above criteria: consultation with sponsor required
B. Prior to RANDOMIZATION in the study 9. Completed primary therapy of breast cancer according to current guidelines, i.e., after (neo)adjuvant treatment, definite surgery and radiotherapy, if applicable.
absolute neutrophil count ≥ 1.5 × 109/L,
platelets ≥ 100 × 109/L,
hemoglobin ≥ 8.0 g/dL,
total bilirubin ≤ 1.5 ULN, except for patients with Gilbert's Syndrome who may only be included if the total bilirubin is ≤ 2.0 × ULN or direct bilirubin within normal ranges,
aspartate transaminase (AST) ≤ 3 × ULN,
alanine transaminase (ALT) ≤ 3 × ULN,
serum creatinine ≤ 1.5 x ULN. 15. Ability to swallow abemaciclib tablets or to administer other study medication, respectively.
Ability to communicate with the investigator and comply with study procedures.
Willing to receive therapy by clinical site, as required by the protocol.
Exclusion criteria
Patients eligible for inclusion in this study must not meet any of the following criteria:
Patient with distant metastases of breast cancer beyond regional lymph nodes.
Previously received CDK 4/6 inhibitor.
Patient with a known hypersensitivity to any of the excipients of abemaciclib or standard-of-care endocrine therapy.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Patient has not recovered from clinical and laboratory acute toxicities related to prior anticancer therapies to NCI CTCAE version 5.0 Grade ≤ 1 (polyneuropathy ≤ 2 is allowed).
Patient has a concurrent malignancy or non-breast malignancy within 5 years prior to randomization.
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small-bowel resection).
Patient has any active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator´s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, etc.).
Patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Patient is currently receiving any of the following substances, which cannot be discontinued 7 days prior to day 1 of study treatment:
o concomitant medications and herbal supplements, that are strong inducers or inhibitors of CYP3A4.
Participation in a prior investigational study within 30 days prior to enrollment.
Not able to understand and to comply with study instructions and requirements.
Pregnant or nursing (lactating) woman.
Woman of child-bearing potential defined as woman physiologically capable of becoming pregnant, unless she is using highly effective methods of contraception during the study treatment and for 21 days after stopping the treatment:
Use of oral (estrogen and progesterone), transdermal, injected, or implanted hormonal methods of contraception as well as hormonal replacement therapy.
Primary purpose
Allocation
Interventional model
Masking
1,260 participants in 2 patient groups
Loading...
Central trial contact
Anja Braschoß, MD; Bettina Bonn, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal